ANN ARBOR, Mich.–(BUSINESS WIRE)– Millendo
Therapeutics, Inc., a clinical-stage biopharmaceutical company
focused on developing novel treatments for endocrine diseases caused by
hormone dysregulation, today announced that Julia C. Owens, Ph.D.,
President and Chief Executive Officer, will present at the UBS Global
Healthcare Conference on Wednesday, May 24, 2017 at 10:00 a.m. EDT in
New York, NY.
About Millendo Therapeutics, Inc.
Millendo Therapeutics is
focused on developing novel treatments for endocrine diseases caused by
hormone dysregulation. Our mission is to build a leading endocrine
company that creates distinct and transformative treatments for a wide
range of diseases where there is a significant unmet medical need. We
are advancing two product candidates in five indications: MLE4901,
designed to address Vasomotor Symptoms (VMS) and Polycystic Ovary
Syndrome (PCOS), and ATR-101 for the treatment of Classic Congenital
Adrenal Hyperplasia (CAH), Endogenous Cushing’s Syndrome (CS), and
Adrenocortical Carcinoma (ACC). www.millendo.com
Image may be NSFW.
Clik here to view.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170517005190/en/
Contacts
Media Contact:
MacDougall Biomedical Communications
Casey
R. Doucette, Ph.D., +1 781-235-3060
cdoucette@macbiocom.com
or
Investor
Contact:
Stern Investor Relations, Inc.
Stephanie Ascher,
+1 212-362-1200
stephanie@sternir.com
Source: Millendo Therapeutics, Inc.
Cet article Millendo Therapeutics to Present at the UBS Global Healthcare
Conference est apparu en premier sur EEI-BIOTECHFINANCES.
